

- M, Seferovic P, Swedberg K, Tomkowski W, Achenbach S, Agewall S, Al-Attar N, Angel Ferrer J, Arad M, Asteggiano R, Bueno H, Caforio ALP, Carerj S, Ceconi C, Evangelista A, Flachskampf F. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2015;**36**: 2921–2964.
67. Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. *Arthritis Rheumatol* 2014;**66**:768–769.
68. Manusow JS, Khoja L, Pesin N, Joshua AM, Mandelcorn ED. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. *J Immunother Cancer* 2014;**2**:41.
69. Padda A, Schiopu E, Sovich J, Ma V, Alva A, Fecher L. Ipilimumab induced digital vasculitis. *J Immunother Cancer* 2018;**6**:12.
70. Burel SL, Champiat S, Mateus C, Marabelle A, Michot J-M, Robert C, Belkhir R, Soria J-C, Laghouati S, Voisin A-L, Fain O, Mékinian A, Coutte L, Szwebel T-A, Dunogean L, Lioger B, Luxembourger C, Mariette X, Lambotte O. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. *Eur J Cancer* 2017;**82**:34–44.
71. Roy AK, Tathireddy HR, Roy M. Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. *BMJ Case Rep* 2017;**2017**. pii: bcr-2017-221852.
72. Arellano K, Mosley JC, Moore DC. Case report of ipilimumab-induced diffuse, non-necrotizing granulomatous lymphadenitis and granulomatous vasculitis. *J Pharm Pract* 2018;**31**:227–229.
73. Brom RRH, van den Abdulahad WH, Rutgers A, Kroesen B-J, Roozendaal C, Groot DJA, de Schröder CP, Hospers GAP, Brouwer E. Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. *Rheumatology (Oxford)* 2016;**55**: 1143–1145.
74. Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors—a systematic review. *Clin Rheumatol* 2018;**37**:2579–2584.
75. Buttgerit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. *JAMA* 2016;**315**:2442–2458.
76. Watanabe R, Zhang H, Berry G, Goronzy JJ, Weyand CM. Immune checkpoint dysfunction in large and medium vessel vasculitis. *Am J Physiol Heart Circ Physiol* 2017;**312**:H1052–H1059.
77. Zhang H, Watanabe R, Berry GJ, Vaglio A, Liao YJ, Warrington KJ, Goronzy JJ, Weyand CM. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. *Proc Natl Acad Sci USA* 2017;**114**:E970–E979.
78. Varricchi G, Galdiero MR, Mercurio V, Bonaduce D, Marone G, Tocchetti CG. Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. *Lancet Oncol* 2018;**19**:1545–1546.
79. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, Fulcher J, Hollywood J, Hutchings A, James P, Kyle V, Nott J, Power M, Samanta A. BSR and BHRP guidelines for the management of giant cell arteritis. *Rheumatology (Oxford)* 2010;**49**:1594–1597.
80. Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. *JAMA Oncol* 2018;**4**:1721–1728.
81. Webster RM. The immune checkpoint inhibitors: where are we now? *Nat Rev Drug Discov* 2014;**13**:883–884.
82. Tocchetti CG, Galdiero MR, Varricchi G. Cardiac toxicity in patients treated with immune checkpoint inhibitors. *J Am Coll Cardiol* 2018;**71**:1765–1767.

Corrigendum

doi:10.1093/cvr/cvz082

Corrigendum to: Cardiovascular toxicities associated with immune checkpoint inhibitors [*Cardiovasc Res* 2019;**115**:854–868].

The authors of the above paper wish to advise that references to Rituximab have been added to the paper. The content of the article has been edited to reflect this change.

The authors apologise for the error.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.